Healthcare / Drug Manufacturers - Specialty & GenericKSE
$7340.00
-210.00 (-2.78%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $1.7B · quality 42.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$82.9B
P/E
7.6x
↓EV/EBITDA
2.5x
↓ROE
6.5%
↑Gross Margin
38.1%
↓Debt/Equity
1.18
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.4%
FCF CAGR
—
FCF margin
1.5%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $590.89B · net income $10.93B · FCF $8.97B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $590.89B | $590.89B | $634.65B | $638.45B | $675.54B |
| Net Income | $10.93B | $10.93B | $63.04B | $-59.59B | $-102.35B |
| EBITDA | $82.84B | $82.84B | $122.15B | $-64.04B | $-116.29B |
| EPS | 967.00 | 967.00 | 5063.00 | -5227.00 | -9555.00 |
| Gross Margin | 38.1% | 38.1% | 35.7% | 33.2% | 35.4% |
| Operating Margin | 2.6% | 2.6% | -0.6% | -12.5% | -14.5% |
| Net Margin | 1.8% | 1.8% | 9.9% | -9.3% | -15.2% |
| Balance Sheet | |||||
| Debt/Equity | 1.18 | 1.18 | 2.43 | 8.35 | 25.32 |
| Current Ratio | 0.83 | 0.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $8.97B | $8.97B | $1.72B | $-77.26B | $-95.73B |
| Returns | |||||
| ROE | 6.5% | 6.5% | 47.1% | -152.9% | -866.4% |
| Valuation | |||||
| P/E | 7.59 | 7.59 | 1.48 | — | — |
| EV/EBITDA | 2.48 | 2.48 | 2.77 | — | — |
| P/B | 0.49 | 0.49 | 0.70 | 2.96 | 17.95 |
| Growth & Yield | |||||
| Revenue Growth | -6.9% | -6.9% | -0.6% | -5.5% | — |
| EPS Growth | -80.9% | -80.9% | 196.9% | 45.3% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-12.3%
EPS terminal req.
$651.30
Spread vs growth
-68.6%
5Y implied EPS CAGR
-4.0%
EPS terminal req.
$788.08
Spread vs growth
-76.9%
10Y implied EPS CAGR
2.8%
EPS terminal req.
$1269.20
Spread vs growth
-83.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+23.2%
Start / end P/E
1.2x → 7.6x
EPS bridge
5063.00 → 967.00
Residual
-435.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.